Related references
Note: Only part of the references are listed.High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
T E Witzig et al.
Blood Cancer Journal (2017)
Immune checkpoint blockade in lymphoid malignancies
Gita Thanarajasingam et al.
FEBS JOURNAL (2016)
Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Minmin Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
M. M. Patnaik et al.
BLOOD CANCER JOURNAL (2016)
Everolimus combined with R-CHOP-21 for new, untreated, diff use large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and effi cacy results of a phase 1 and feasibility trial
Patrick B. Johnston et al.
LANCET HAEMATOLOGY (2016)
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
T. E. Witzig et al.
ANNALS OF ONCOLOGY (2015)
Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis
Kasper D. Rasmussen et al.
GENES & DEVELOPMENT (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Role of DNA methylation in renal cell carcinoma
Niraj Shenoy et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
TET proteins and the control of cytosine demethylation in cancer
Laurianne Scourzic et al.
GENOME MEDICINE (2015)
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide et al.
BLOOD (2014)
Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival
Caroline Y. Hu et al.
CLINICAL CANCER RESEARCH (2014)
Origins of aberrant DNA methylation in acute myeloid leukemia
T. Schoofs et al.
LEUKEMIA (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
Yan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
Eric Letouze et al.
CANCER CELL (2013)
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Christopher M. Stephenson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals
Ruichuan Yin et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells
Kathryn Blaschke et al.
NATURE (2013)
Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
Thomas Clozel et al.
CANCER DISCOVERY (2013)
Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity
Subhajyoti De et al.
PLOS GENETICS (2013)
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
Francois Lemonnier et al.
BLOOD (2012)
Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
Daniel A. Monti et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Epigenetic Changes in the Myelodysplastic Syndrome
Jean-Pierre Issa
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects
Julien Verrax et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
L. J. Hoffer et al.
ANNALS OF ONCOLOGY (2008)
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Peter H. Wiernik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice
Qi Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo
Qi Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues
Q Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Vitamin C deficiency and depletion in the United States: The Third National Health and Nutrition Examination Survey, 1988 to 1994
JS Hampl et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2004)
Share Paper
